|1.||Suzuki, Tsutomu: 2 articles (10/2013 - 09/2013)|
|2.||Mori, Tomohisa: 2 articles (10/2013 - 09/2013)|
|3.||Shibasaki, Masahiro: 2 articles (10/2013 - 09/2013)|
|4.||Felippotti, Tatiana Tocchini: 2 articles (02/2012 - 12/2011)|
|5.||Coimbra, Norberto Cysne: 2 articles (02/2012 - 12/2011)|
|6.||Wang, Erika: 1 article (10/2013)|
|7.||Yoshizawa, Kazumi: 1 article (10/2013)|
|8.||Hasegawa, Minami: 1 article (10/2013)|
|9.||Masukawa, Daiki: 1 article (10/2013)|
|10.||Shibasaki, Yumiko: 1 article (10/2013)|
02/01/2012 - "Neither acute (10-min) peripheral pre-treatment with naloxonazine nor subchronic intramesencephalic blockade of μ1-opioid receptors resulted in consistent statistically significant differences in the severity of tonic-clonic seizures shown by Racine's index (1972), although the intracollicular specific antagonism of μ1-opioid receptor decreased the duration of seizures. "
02/01/2012 - "In addition, microinjections of naloxonazine into the central, dorsal cortical and external cortical nuclei of the inferior colliculus antagonised tonic-clonic seizure-induced antinociception. "
02/01/2012 - "Peripheral subchronic (24 h) pre-treatment with naloxonazine antagonised the antinociception elicited by tonic-clonic seizures. "
12/01/2011 - "However, naloxonazine treatment 24 hours before PTZ decreased post-ictal antinociception, but DNC failed to antagonize tonic-clonic seizure-induced analgesia. "
11/06/1992 - "The selective mu 1-antagonists naloxonazine and naltrexonazine promoted the clonic phase of electrically induced convulsion in C57BL/6 mice. "
01/01/1988 - "Naloxonazine (10 mg/kg) failed to affect EKC hyperphagia. "
09/19/1994 - "Carbohydrate or fat preference in glucoprivic rats significantly increased the amount of explained variance in the inhibitory action of systemic and central naltrexone, B-FNA, naloxonazine and Nor-BN upon 2-DG hyperphagia. "
05/03/1991 - "In contrast, insulin hyperphagia was only transiently (2 h) inhibited (27-30%) by either the irreversible mu 1 antagonist, naloxonazine (50 micrograms, i.c.v.) or the selective kappa antagonist, nor-binaltorphamine (NorBNI, 20 micrograms, i.c.v.). "
01/01/1988 - "Naloxonazine (10 mg/kg) shifted the morphine hyperphagia dose-response curve to the right. "
04/01/1988 - "The mu-1 sites have been implicated in free-feeding, deprivation-induced feeding and morphine-induced hyperphagia, based upon their sensitivity to both naloxone and naloxonazine. "
12/01/2011 - "This study characterizes the effect of a dendrimer-naloxonazine complex on μ1 receptor-mediated post-ictal antinociception in an animal model of seizure disorder."
01/01/2013 - "EA-induced augmentation of epileptic activity was blocked by microinjection of naloxone, μ- (naloxonazine), κ- (nor-binaltorphimine) or δ-receptor antagonists (natrindole) into the CeA, suggesting that activation of opioid receptors in the CeA mediates EA-exacerbated epilepsy. "
10/01/1989 - "To further study the site of action for the effect of naloxone, we measured baroreflex sensitivity in the dogs with heart failure after pretreatment with naloxonazine, a selective mu-receptor antagonist, with ICI 154,129, a selective delta-receptor antagonist, or with naloxone methobromide, a quaternary analogue of naloxone that does not penetrate the blood-brain barrier.(ABSTRACT TRUNCATED AT 250 WORDS)"
11/25/1996 - "The present study examined whether centrally administered general (naltrexone: 1-50 micrograms), mu (beta-funaltrexamine: 1-20 micrograms), mu 1 (naloxonazine: 50 micrograms), kappa 1 (nor-binaltorphamine: 1-20 micrograms), delta 1 ([D-Ala2, Leu5, Cys6]-enkephalin: 10-40 micrograms) or delta 2 (naltrindole isothiocyanate: 20 micrograms) opioid subtype antagonists altered either maltose dextrin (10%) intake during sham feeding or deprivation (24 h)-induced water intake during sham drinking in rats with gastric fistulas. "
|3.||Opioid Receptors (Opioid Receptor)
|7.||Morphine (MS Contin)
|9.||mu Opioid Receptors (mu Opioid Receptor)
|2.||Induced Hyperthermia (Thermotherapy)